- Open Access
Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review
© The Author(s). 2016
Received: 22 July 2015
Accepted: 31 May 2016
Published: 9 June 2016
The objective of this study is to evaluate the efficacy of adjuvant interferon therapy for hepatitis B virus-related hepatocellular carcinoma (HCC) after different previous therapy.
An electronic search for articles about adjuvant treatment with IFN for patients with HCC published between 2000 and 2015 was conducted in MEDLINE, PubMed, Cochrane Library, and EMBASE databases. All data was tested with Stata12.0 software.
Six trials with a total of 1054 subjects were screened according to inclusion and exclusion standards. Five hundred and seventeen HCC patients were treated with adjuvant treatment with IFN and 537 patients with placebo. Compared to the control group, both the recurrence rate and death rate of HCC in IFN group were statistically lower, especially after transhepatic arterial chemotherapy and embolization (TACE) treatment and both TACE and resection according to subgroup analysis.
There is no statistical significance on the both recurrence and death rate of HBV-related hepatocellular carcinoma after surgical resection treatment (RR = 0.96, 95 % CI, 0.84 to 1.1, p = 0.59 for recurrence and RR = 0.78, 95 % CI, 0.60 to 1.04, p = 0.09 for death rates).
Adjuvant IFN therapy may significantly reduced mortality as well as recurrence rate of patients with HBV-related HCC after no matter what the previous treatment. On the other hand, there is no statistical significance on the recurrence rate and mortality after surgical resection only. More research is needed into the relationship between effect of adjuvant interferon therapy and previous therapy, especially TACE.
Primary liver cancer is mainly composed of hepatocellular carcinoma (HCC), which is the world’s third most common cause of cancer deaths . About 55 % liver cancer deaths worldwide occur in China, because of the highest age-adjusted incidence of HCC due to chronic hepatitis B (CHB) . Due to the high difficulty in early diagnosis of malignant tumors, most of cancer metastasis have occurred for the first time seeing a doctor . Most patients received surgical resection or transhepatic arterial chemotherapy and embolization (TACE) . Unfortunately, the recurrence rate after 3 years of liver cancer which is treated by pure resection or chemotherapy via hepatic artery embolism is more than 50 %, which is the main cause of death after treatment [5, 6]. Most HCC patients carry with hepatitis virus, which is one of the three main complications of patients with CHB, resulting in one million deaths each year [6, 7] and, of these, nearly 500,000 deaths are in China . Studies have suggested interferon can reduce the recurrence of HCC after treatment, because interferon can inhibit the replication of the hepatitis virus and kill cancer cells, but the conclusion is not consistent [8–11].
In this paper, the clinical data is put forward by evidence-based medicine system evaluation, and a meta-analysis using fixed/random effects model is used to study the influence of recurrence rate and mortality of viral hepatitis liver cancer, which is treated by interferon after surgical resection or TACE or both surgical resection and TACE, and provide the foundation for evidence-based medicine.
We reviewed all the experimental results of the curative effect of interferon adjuvant treating patients with HCC. Computerized literature searches of PubMed, the Cochrane Library, and EMBASE database (2005–2015) were undertaken. Search words were “hepatocellular carcinoma,” “liver cancer,” “liver tumor,” “interferon.” Review was conducted with these terms separately in different combinations. In addition, references catalog of relevant original articles and comments were reviewed to find out other qualified trials.
Inclusion and exclusion criteria
The inclusion criteria are as follows: (1) All the cases were pathologically diagnosed as liver cancer combined with viral-B hepatitis; (2) both interferon group and control group were treated by surgical removal or TACE; (3) the interferon adjuvant therapy was given after the first treatment (surgical removal, TACE) for more than 3 months; (4) the follow-up time must be more than 1 year, and the control group was treated with placebo; and (5) the sample size >35.
The exclusion criteria are as follows: (1) Metastatic liver cancer or recurrent liver cancer has been treated; (2) repetitive articles and small proportion articles; (3) the follow-up time was less than 1 year; and (4) the sample size <35.
Two reviewers independently extracted all literatures to determine if the relevant trials meet the included criteria.
Quality of assessment of each included studies
Lost of follow-up
The review management software (Stata) is used for statistical analysis, and all outcomes were expressed as RR with 95 % CI. The Cochrane Q test was used to detect heterogeneity of the effects; significant heterogeneity was defined as a p value <0.1. A fixed effects model or random effects model was used depending on the absence or presence of heterogeneity. I 2 statistic was estimated to describe the percentage of the variability attributable to heterogeneity. Studies with an I 2 statistic of <25 % are considered to have no heterogeneity, those with an I 2 statistic of 25–50 % are considered to have low heterogeneity, and those with an I 2 statistic of 50–75 % are considered to have moderate heterogeneity, in which the random effects model was used.
Two hundred and nineteen relevant articles were retrieved through combined manual and computerized retrieval in the MEDLINE, PubMed, the Cochrane Library, and EMBASE database from 2005–2015. One hundred and thirty-six articles were excluded, because the title and abstract has nothing to do with the purpose of this meta-analysis. Finally, 6 articles and a total of 1054 subjects were included in the systematic review, including 4 randomized controlled trials and 2 nonrandomized controlled trials.
Four trials examined the effect of IFN after surgical resection and one trial after TACE only and the other after both surgical resection and TACE.
Details of included studies
Median follow-up time (m)
Resection + TACE
IFN + TACE.
Minimum follow-up 30
Recurrence of hepatocellular carcinoma
Six articles [10–15], including 1054 patients, compared the recurrence of hepatocellular carcinoma in the interferon group and the control group. We used “RR” as an indicator of testing method of therapeutic effect and used X 2 test to examine heterogeneity, and the result was p = 0.72 (>0.10), I 2 = 0 % (<50 %), which suggested no heterogeneity between the two groups. The fixed effects model was used for meta-analysis. Results (RR = 0.90, 95 % CI, 0.83 to 0.99, p = 0.02) showed that interferon adjuvant therapy can significantly reduce the recurrence rate of HCC after initial treatment, especially after TACE treatment and both TACE and surgical resection treatment according to subgroup analysis (RR = 0.80, 95 % CI, 0.65 to 0.99, p = 0.04 for TACE; and RR = 0.87, 95 % CI, 0.78 to 0.98, p = 0.02 for both TACE and surgical resection). Pooled data analysis revealed that the interferon group had no statistical significance on the recurrence of HBV-related hepatocellular carcinoma after surgical resection treatment (RR = 0.96, 95 % CI, 0.84 to 1.1, p = 0.59).
Death rates for hepatocellular carcinoma
Something similar seems to be happening in death rate. With the same articles, we compared the death rate of hepatocellular carcinoma in the interferon group and the control group. The result was p = 0.67 (>0.10), I 2 = 51.4 % (>50 %), and the unfixed effects model was used for meta-analysis. The death rate in the IFN group also significantly decreased according to not only total event analysis (RR = 0.72, 95 % CI, 0.60 to 0.87, p = 0.001) but also subgroup analysis (RR = 0.75, 95 % CI, 0.63 to 0.90, p = 0.002 for both TACE and surgical resection; and RR = 0.56, 95 % CI, 0.43 to 0.73, p = 0.000 for TACE). But, as well, there is no statistical significance on the mortality of HBV-related hepatocellular carcinoma after surgical resection treatment (RR = 0.78, 95 % CI, 0.60 to 1.04, p = 0.09).
Sensitivity analysis and publication bias
(Begg’s test statistic, p = 0.45; Egger’s test statistic, p = 0.52 for the funnel plots of recurrence; Begg’s test statistic, p = 0.71; Egger’s test statistic, p = 0.98 for the funnel plots of death rates.)
HCC is the third leading cause of cancer-related deaths worldwide , which has one of the most common risk factors, HBV [16, 17], especially in Asian countries where HBV has a higher incidence . Eighty-five to ninety percent of HCC contain HBV-DNA-integrated tumor cells, providing the strongest evidence for HBV-DNA integration being the primary etiology of CHB-related HCC . Hepatic resection or liver transplantation may provide a complete cure for HCC. However, postoperative recurrence is a big concern . Most recurrences occur within 1 year after surgery. HCC recurrence rate is also relatively high in patients who had liver transplantations .
In clinical work, the main method of treatment of liver cancer is surgery and TACE . In order to eliminate deviation caused by different treatment methods, this paper chose the surgery, TACE, and both TACE and surgery resection to treat liver cancer and determined the difference between the two methods through subgroup analysis. The results showed that both the recurrence and mortality of liver cancer had significant differences between interferon group and the control group. But, there is no statistical significance on the recurrence rate and mortality of HBV-related hepatocellular carcinoma after surgical resection only. This result was contrary to the meta-analyses or systematic reviews published before . One of the meta-analysis reported by Zhang included one trial less than ours. And, this trial  was published recently by Zuo, and its conclusion was contrary to the trials which were included in Zhang’s report. Meanwhile, samples in Zuo’s report were larger than any other RCTs [10–15], which were all included in our meta-analysis. So, the weight of the trial largely affected the final results, different conclusion achieved is reasonable. Still, it is worth noting that the added article is a nRCT.
Interferon has many biological functions, such as antiviral, antiproliferative, antiangiogenic, and immunomodulatory effects, and it is widely used in the treatment of various diseases [24, 25]. In vitro experiments showed that  alpha interferon can inhibit the proliferation of endothelial cells of human umbilical vein, and its inhibition function increased with dose and time increased. In vivo experiments showed that  tumor diameter is decreased obviously after adjuvant therapy with interferon, and microvascular density was obviously lower than the control group, and there was significant difference. So, it is presumable that alpha interferon realizes its antitumor effect by inhibiting tumor angiogenesis and anticell proliferation. The above biological characteristics can explain the interferon adjuvant therapy is beneficial for the treatment of liver cancer.
On the other hand, some studies found that the efficacy of IFN on inducing hepatitis Be antigen (HBeAg) seroconversion is not so good  and the sustained virologic response rate was only 25 % . But, the main effects of interferon are antiviral, immune regulation, and antiproliferative agents rather than the integration of HBV gene inhibitors . Interferon treatment improves liver fibrosis and liver function by reducing active hepatitis , and it can improve overall survival by reducing the severity of the recurrence of the tumor, so it is suitable for secondary therapeutic ablation or resection . From the above description, we can draw the conclusion: interferon does not prevent HBV-related HCC, but there is still a long-term effective effect for viral hepatitis-related HCC.
Several limitations of this study should be considered: (1) Although most of the studies are randomized controlled trials, the sample sizes are relatively small; (2) the basic characteristics of included cases were not identical, and the effect factors (including the clinical stages, pathological pattern, therapeutic method, the size of the tumor, and the body’s immune ability), which influenced clinical prognosis of hepatocellular carcinoma, may affect the results of the meta-analysis; and (3) the included studies mostly reported the recurrence rate and mortality, but there are less reports on overall survival rate and disease-free survival (DFS) of interferon adjuvant therapy.
In short, the meta-analysis, which included six literatures, indicated that interferon adjuvant therapy can significantly reduce the recurrence rate of viral hepatitis-related hepatocellular carcinoma and improve the survival rate of patients after no matter previous treatment is given including surgical resection and TACE. On the other hand, there is no statistical significance on the recurrence rate and mortality of HBV-related hepatocellular carcinoma after surgical resection only. More research is needed into the relationship between effect of adjuvant interferon therapy and previous therapy, especially TACE.
The authors thank Xiaoqiang Zhandui and Dr Yuan Gao, who have been a source of encouragement and inspiration.
QS and QL participated in the design of the study and performed the statistical analysis. WL, GW, and SY conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.View ArticlePubMedGoogle Scholar
- McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3–23.View ArticlePubMedGoogle Scholar
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17.View ArticlePubMedGoogle Scholar
- Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.View ArticlePubMedGoogle Scholar
- Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.View ArticlePubMedGoogle Scholar
- Chen SJ, Zhao YX, Fang Y, Xu WZ, Ma YX, Song ZW, et al. Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection. Virus Res. 2012;163(1):197–201.View ArticlePubMedGoogle Scholar
- Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100(2):376–82.View ArticlePubMedGoogle Scholar
- Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta Medica Okayama. 2005;59(5):217–24.PubMedGoogle Scholar
- Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458–65.View ArticlePubMedGoogle Scholar
- Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255(1):8–17.View ArticlePubMedGoogle Scholar
- Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245(6):831–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, et al. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. Journal Gastroenterol Hepatol. 2009;24(8):1437–44.View ArticleGoogle Scholar
- Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17(1):179–85.View ArticlePubMedGoogle Scholar
- Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, et al. Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pacific journal of cancer prevention : APJCP. 2015;16(1):245–51.View ArticlePubMedGoogle Scholar
- Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. J Gastroenterol Hepatol. 2011;9(7):617–23. e1.Google Scholar
- Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011;9(1):64–70.View ArticleGoogle Scholar
- Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800.View ArticlePubMedGoogle Scholar
- Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007;252(2):157–70.View ArticlePubMedGoogle Scholar
- Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, et al. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2009;35(2):174–9.View ArticlePubMedGoogle Scholar
- Ibrahim S, Roychowdhury A, Hean TK. Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg. 2007;194(1):17–22.View ArticlePubMedGoogle Scholar
- Marrero J. Current treatment approaches in HCC. Clin Adv Hematol Oncol. 2013;11 Suppl 5(4):15––8.Google Scholar
- Zhang W, Song T, Zhang T, Wu Q, Kong D, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2(6):1125–34.PubMedPubMed CentralGoogle Scholar
- Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol. 2003;18(6):630–7.View ArticlePubMedGoogle Scholar
- Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, et al. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nature Immunol. 2013;14(8):793–803.View ArticleGoogle Scholar
- Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, et al. Interferon-alpha enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer. 2012;11:31.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potentia. Hepatol (Baltimore, Md). 2000;32(1):43–8.View ArticleGoogle Scholar
- Ji YJ, Li FF, Ren WH, Zhu YH, Qin CY. Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chinese J Hepatol. 2013;21(5):335–9.Google Scholar
- Liaw YF. Hepatitis B, virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther. 2006;11(6):669–79.PubMedGoogle Scholar
- Ormeci N. Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol. 2003;17(6):651–8.View ArticlePubMedGoogle Scholar
- Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357(9251):196–7.View ArticlePubMedGoogle Scholar
- Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006;33(3):121–8.View ArticlePubMedGoogle Scholar